ISSN: 2040-6223

Journal Home

Therapeutic Advances in Chronic Disease Q1 Unclaimed

SAGE Publications Inc. United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Therapeutic Advances in Chronic Disease is a journal indexed in SJR in Medicine (miscellaneous) with an H index of 54. It is an CC BY-NC Journal with a Single blind Peer Review review system, and It has a price of 1800 €. The scope of the journal is focused on pharmacology, chronic conditions, chronic diseases. It has an SJR impact factor of 0,966 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 0,966.

Type: Journal

Type of Copyright: CC BY-NC

Languages: English

Open Access Policy: Open Access

Type of publications:

Publication frecuency: -

Categories: Medicine (miscellaneous) (Q1)

Price

1800 €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

0,966

SJR Impact factor

54

H Index

38

Total Docs (Last Year)

317

Total Docs (3 years)

1735

Total Refs

998

Total Cites (3 years)

307

Citable Docs (3 years)

2.96

Cites/Doc (2 years)

45.66

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

MMWR. Morbidity and mortality weekly report Q1
Annual Review of Public Health Q1
Annual Review of Clinical Psychology Q1
Journal of Thoracic Oncology Q1
Lancet Digital Health, The Q1

Compare this journals

Aims and Scope

Pharmacology Chronic conditions Chronic diseases

Best articles by citations

New anticoagulants in atrial fibrillation: an update for clinicians

Dolutegravir: clinical efficacy and role in HIV therapy

Glaucoma management: relative value and place in therapy of available drug treatments

No clear relationship between antihypertensive class and cognitive function over 12 months in a cohort study of community-dwelling adults aged 80 and over

Current and emerging therapies for the management of functional gastrointestinal disorders

Targeted metabolomic analysis of serum phospholipid and acylcarnitine in the adult Fontan patient with a dominant left ventricle

Retinal correlates of psychiatric disorders

Rifaximin in irritable bowel syndrome: rationale, evidence and clinical use

The perceptions of natural compounds against dipeptidyl peptidase 4 in diabetes: from in silico to in vivo

The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity

Predictors of lithium response in bipolar disorder

Prescribing attitudes, behaviors and opinions regarding metformin for patients with diabetes: a focus group study

SHOW MORE ARTICLES

Contributors, risk associates, and complications of frailty in patients with chronic kidney disease: a scoping review

Psoriatic arthritis: latest treatments and their place in therapy

The role of oesophageal physiological testing in the assessment of noncardiac chest pain

Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidance

Cognitive dysfunction with aging and the role of inflammation

The association of physical function and physical activity with all-cause mortality and adverse clinical outcomes in nondialysis chronic kidney disease: a systematic review

Effects of vitamin D on muscle function and performance: a review of evidence from randomized controlled trials

Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implications

Killing two birds with one stone: successful opioid monotherapy in intractable migraine-triggered epilepsy, a case series

The updated PIM-Taiwan criteria: a list of potentially inappropriate medications in older people

Statin use in prediabetic patients: rationale and results to date

Pegylated interferon and ribavirin treatment for hepatitis C virus infection